Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
First Claim
1. A purified and isolated non-naturally occurring RNA ligand to Vascular Endothelial Growth Factor wherein said ligand is comprised of 2'"'"'fluoro (2'"'"'F)-modified nucleotides.
4 Assignments
0 Petitions
Accused Products
Abstract
This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.
-
Citations
21 Claims
- 1. A purified and isolated non-naturally occurring RNA ligand to Vascular Endothelial Growth Factor wherein said ligand is comprised of 2'"'"'fluoro (2'"'"'F)-modified nucleotides.
- 2. A method for improving the pharmacokinetic properties of VEGF Nucleic Acid Ligand in an occular application comprising covalently linking a Non-Immunogenic, High Molecular Weight compound to a VEGF Nucleic Acid Ligand to form a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound.
Specification